SLC5A3: A Potential Drug Target and Biomarker for Cancer (G6526)

Target Name: SLC5A3

NCBI ID: G6526

SLC5A3

SLC5A3: A Potential Drug Target and Biomarker for Cancer

SLC5A3 (Simple Localization of Cell Membrane Proteins) is a protein that is expressed in various cell types of the human body, including epithelial, endothelial, and immune cells. It is a member of the SLC family of transmembrane proteins, which are known for their ability to transport various molecules across cell membranes. SLC5A3 is a 26kDa protein that consists of 116 amino acid residues.

SLC5A3 is involved in many different cellular processes in the human body, including cell signaling, inflammation, and stress responses. One of its most well-known functions is its role in cell signaling, particularly in the regulation of cell proliferation. SLC5A3 has been shown to play a negative role in the regulation of cell proliferation, by inhibiting the inhibition of apoptosis (programmed cell death) in cancer cells.

In addition to its role in cell signaling, SLC5A3 is also involved in the regulation of inflammation and stress responses. It has been shown to play a positive role in the regulation of inflammation, by promoting the production of pro-inflammatory cytokines. SLC5A3 has also been shown to play a negative role in the regulation of stress responses, by preventing the activation of stress-induced cell proliferation in cancer cells.

SLC5A3 is also a potential drug target in cancer, due to its involvement in the regulation of cell proliferation and stress responses. Many studies have shown that inhibiting SLC5A3 function can lead to the inhibition of cancer cell growth and the regression of cancer tumors. In addition, SLC5A3 has been shown to be involved in the regulation of stem cell self-renewal and differentiation, which may make it a useful target for the treatment of stem cell disorders.

Furthermore, SLC5A3 has also been suggested as a potential biomarker for cancer diagnosis and monitoring. The expression of SLC5A3 has been shown to be decreased in various types of cancer, including breast, ovarian, and colorectal cancer. Additionally, SLC5A3 has been shown to be involved in the regulation of cell cycle progression, which may be an attractive target for the development of biomarkers for cancer diagnosis and monitoring.

In conclusion, SLC5A3 is a protein that is expressed in various cell types of the human body, and is involved in a wide range of cellular processes in the body. Its role in cell signaling, inflammation, and stress responses makes it a potential drug target and biomarker for cancer. The inhibition of SLC5A3 function has been shown to lead to the inhibition of cancer cell growth and the regression of cancer tumors, making it a promising target for the treatment of cancer. Further research is needed to fully understand the role of SLC5A3 in cellular processes and its potential as a drug target and biomarker for cancer.

Protein Name: Solute Carrier Family 5 Member 3

Functions: Electrogenic Na(+)-coupled sugar symporter that actively transports myo-inositol and its stereoisomer scyllo-inositol across the plasma membrane, with a Na(+) to sugar coupling ratio of 2:1 (By similarity). Maintains myo-inositol concentration gradient that defines cell volume and fluid balance during osmotic stress, in particular in the fetoplacental unit and central nervous system (By similarity). Forms coregulatory complexes with voltage-gated K(+) ion channels, allosterically altering ion selectivity, voltage dependence and gating kinetics of the channel. In turn, K(+) efflux through the channel forms a local electrical gradient that modulates electrogenic Na(+)-coupled myo-inositol influx through the transporter (PubMed:24595108, PubMed:28793216). Associates with KCNQ1-KCNE2 channel in the apical membrane of choroid plexus epithelium and regulates the myo-inositol gradient between blood and cerebrospinal fluid with an impact on neuron excitability (PubMed:24595108) (By similarity). Associates with KCNQ2-KCNQ3 channel altering ion selectivity, increasing Na(+) and Cs(+) permeation relative to K(+) permeation (PubMed:28793216). Provides myo-inositol precursor for biosynthesis of phosphoinositides such as PI(4,5)P2, thus indirectly affecting the activity of phosphoinositide-dependent ion channels and Ca(2+) signaling upon osmotic stress (PubMed:27217553)

The "SLC5A3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC5A3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets